BackManhattan Scientifics Overview

Manhattan Scientifics EBIT

Latest ebit for MHTX: $-680K, below the Industrials sector average of $41B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$160.00K
↑ 13.98% YoY

As of Jun 30, 2024

Annual EBIT (TTM)

-$681.50K
↑ 4.65% YoY

Trailing 12 months ending Jun 30, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Manhattan Scientifics (MHTX) FAQ

The latest EBIT for MHTX is $-680K as of June 2024. That compares with $-710K in the prior-year period — up 4.7% year over year. That is below the Industrials sector average of $41B. Investors often review this figure alongside Manhattan Scientifics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MHTX's EBIT moved from $-710K to $-680K — a 4.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Manhattan Scientifics's operating scale or balance-sheet position.

Against Industrials companies, MHTX currently prints $-680K for EBIT, while the sector average sits near $41B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Manhattan Scientifics's growth, margins, and balance sheet.

A EBIT figure of $-680K for MHTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Industrials average is about $41B. Explore the charts below for those layers of context.

After noting MHTX's EBIT ($-680K), review year-over-year change from $-710K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.